Archive for the ‘SCIENCE’ category

Study: Hemp Seed Oil Associated With Improved Clinical and Immunological Parameters In Multiple Sclerosis Patients

May 24th, 2013

The consumption of legal hemp seed nutritional oil, in conjunction with the intake of evening primrose oils and a restricted diet high in Hot-natured foods (such as pepper) and low in saturated fats and sugars, is associated with “significant improvement” in symptom management and immunological characteristics in subjects with multiple sclerosis, according to clinical trial data published this month in the scientific journal BioImpacts.

Researchers at Tabriz University of Medical Sciences in Iran assessed the impact of hemp seed oil, evening primrose oils, and a restricted diet for a period of six months in 23 patients diagnosed with relapsing remitting MS. Researchers reported that participants at the study’s completion “were healthier in comparison to baseline,” concluding that “clinical and immunological parameters showed improvement in the patients after the intervention.” They noted that hemp seed oil possesses potent antioxidative properties and also likely acts on specific signaling pathways that regulate inflammatory responses — two characteristics that would presumably make it beneficial in the treatment of MS.

Authors concluded: “After 6 months, significant improvements in extended disability status score were found. … [O]ur study demonstrates for the first time in the literature a decrease in both clinical and pro- inflammatory disease activity in MS patients during periods of dietary intervention. Our data demonstrated that co-supplemented hemp seed and evening primrose oils with Hot-natured diet intervention may decrease the risk of developing MS.”

Previously published clinical trials assessing the impact of inhaled cannabis and extracted organic cannabinoids in patients with MS have demonstrated that plant cannabinoids can alleviate disease symptoms — such as involuntary spasticity, neuropathy, and bladder dysfunction — and, in some subjects, may actually moderate disease progression. Nonetheless, the National MS Society shares little enthusiasm for cannabis or cannabis-derived products as a therapeutic option for MS patients, stating on its website: “[B]ased on the studies to date — and the fact that long-term use of marijuana may be associated with significant, serious side effects — it is the opinion of the National Multiple Sclerosis Society’s Medical Advisory Board that there are currently insufficient data to recommend marijuana or its derivatives as a treatment for MS symptoms.”

Study Substantiates Benefits Of Cannabinoids For Post Traumatic Stress

May 21st, 2013

Brain imaging research published this month in the journal Molecular Psychiatry provides physiological evidence as to why cannabis may mitigate certain symptoms of post-traumatic stress disorder (PTSD)

Post-traumatic stress syndrome is an anxiety disorder that is estimated to impact some eight million Americans annually. Yet, to date, there are no pharmaceutical treatments specifically designed or approved to target symptoms of PTSD.

Investigators at the New York University School of Medicine and the New York University Langone Medical Center, Steven and Alexandra Cohen Veterans Center for the Study of Post-Traumatic Stress and Traumatic Brain Injury reported that subjects diagnosed with PTSD typically possess elevated quantities of endogenous cannabinoid receptors in regions of the brain associated with fear and anxiety. Investigators also determined that many of these subjects experience a decrease in their natural production of anandamide, an endogenous cannabinoid neurotransmitter, resulting in an imbalanced endocannibinoid regulatory system.

Researchers speculated that an increase in the body’s production of cannabinoids would likely restore subjects’ natural brain chemistry and psychological balance. They affirmed, “[Our] findings substantiate, at least in part, emerging evidence that … plant-derived cannabinoids such as marijuana may possess some benefits in individuals with PTSD by helping relieve haunting nightmares and other symptoms of PTSD.”

They concluded: “The data reported herein are the first of which we are aware of to demonstrate the critical role of CB1 (cannabinoid) receptors and endocannabinoids in the etiology of PTSD in humans. As such, they provide a foundation upon which to develop and validate informative biomarkers of PTSD vulnerability, as well as to guide the rational development of the next generation of evidence-based treatments for PTSD.”

Anecdotal evidence and case study reports have increasingly indicated that cannabis may mitigate traumatic memories and anxiety. However, clinical trial data remains unavailable, in large part because US federal officials have blocked investigators’ efforts to study cannabis in PTSD subjects. In 2011 federal administrators halted efforts by investigators at the University of Arizona to complete an FDA-approved, placebo-controlled clinical trial to evaluate the use of cannabis in 50 veterans with treatment-resistant PTSD.

PTSD is also seldom identified as a qualifying condition in states that allow for the physician authorized use of cannabis therapy. (To date, only New Mexico explicitly cites PTSD as a qualifying condition for cannabis treatment, although a handful of other states, like California, allow doctors the discretion to legally recommend marijuana for post-trauma subjects.) In Oregon, lawmakers in the House are considering Senate-approved legislation, SB 281, that would allow PTSD patients to legally consume cannabis under the state’s nearly 15-year-old medical marijuana program.

Illinois Senate Passes Medical Marijuana Measure, Goes to the Governor’s Desk

May 17th, 2013

This afternoon, the Illinois State Senate voted 35 to 21 in favor of House Bill 1, which would establish a medical marijuana pilot program in the state. The measure had previously been approved by the House of Representatives and moves to the Governor Pat Quinn’s desk for his signature. While Governor Quinn hasn’t taken a firm stance on HB 1, Lt. Governor Sheila Simon has been open in regards to her support for this legislation.

You can read the full text of the measure here.

NORML will keep you updated as this story develops.

Study: Student Drug Testing Programs Linked To Spikes In ‘Hard’ Drug Use

May 16th, 2013

Schools that institute student drug testing programs are likely to experience a rise in students’ consumption of ‘hard’ drugs, according to observational trial data published this week in the Journal of Adolescent Health.

Researchers at the University of Michigan, Institute for Social Research analyzed the impact of student drug testing programs in some 250,000 high-school and middle-school students over a 14 year period. Investigators reported that random drug testing programs of the student body and programs specifically targeting student athletes were associated with “moderately lower marijuana use,” but cautioned that drug testing programs overall were “associated with increased use of illicit drugs other than marijuana.”

An estimated 14 percent of middle school students and 28 per cent of US high school students are now subject to some form of drug testing.

Urinalysis, the most common form of student drug testing, screens for the presence of inert drug metabolites (breakdown products), not the actual parent drug. Because marijuana’s primary metabolite, carboxy-THC, is fat soluble, it may be present in urine for days, weeks, or in some cases even months after past use. By contrast, most other illicit drug metabolites are water soluble and will exit the body within a matter of hours. Authors of the study speculated that students subjected to drug screens were switching from cannabis to other illicit drugs which possessed shorter detection times.

“Random SDT (student drug testing) among the general high school student population, as well as middle and high school subgroups targeted for testing, was associated with moderately lower marijuana use; however, most forms of testing were associated with moderately higher use of other illicit drugs, particularly in high school,” the authors concluded. “These findings raise the question of whether SDT is worth this apparent tradeoff.”

Commenting on the findings, the study’s lead author affirmed, “It is clear that drug testing is not providing the solution for substance-use prevention that its advocates claim.”

Previous assessments of student drug testing programs have reported that those subjected to such programs are no less likely to report consuming illicit drugs, tobacco, or alcohol than their peers.

The abstract of the study, “Middle and High School Drug Testing and Student Illicit Drug Use: A National Study 1998–2011,” is available online here.

Study: Regular Cannabis Use Associated With Reduced Risk Factors For Type 2 Diabetes

May 15th, 2013

Subjects who regularly consume cannabis possess favorable indices related to diabetic control as compared to occasional consumers or non-users, according to trial data published today online in the American Journal of Medicine.

Here is a summary of the study from the website diabetes.co.uk:

Cannabis may prevent development of type 2 diabetes

A new study has revealed that smoking cannabis may help protect against type 2 diabetes after researchers in the US found that regular users of the drug have better blood sugar control.

Murray Mittleman, of the Cardiovascular Epidemiology Research Unit at the Beth Israel Deaconess Medical Centre in Boston, analysed data on almost 5,000 patients who were quizzed about their use of recreational drugs as part of the National Health and Nutrition Survey between 2005 and 2010.

They found that 2,103 had never use cannabis, 975 had used the drug in the past but were not current users, and 579 (over 10%) had inhaled or ingested it in the past month.

Tests showed that current users had 16% lower fasting insulin levels and reduced insulin resistance than those who had never used cannabis. Non-users also had larger waistlines and lower levels of high-density lipoprotein (HDL or ‘good’) cholesterol – both of which are risk factors for type 2 diabetes.

The same benefits were seen among participants who had used the drug in the past but the associations were not as strong, indicating that the effects of cannabis use on insulin levels and insulin sensitivity wear off over time.

“Previous epidemiologic studies have found lower prevalence rates of obesity and diabetes mellitus in marijuana users compared to people who have never used marijuana, suggesting a relationship between cannabinoids and peripheral metabolic processes, but ours is the first to investigate the relationship between marijuana use and fasting insulin, glucose, and insulin resistance,” said lead investigator Mittleman.

Commenting on the study, American Journal of Medicine Editor-in-Chief Joseph S. Alpert, MD, Professor of Medicine at the University of Arizona College of Medicine, Tucson, wrote in an accompanying commentary: “These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions.” He added: “We desperately need a great deal more basic and clinical research into the short- and long-term effects of marijuana in a variety of clinical settings such as cancer, diabetes, and frailty of the elderly. I would like to call on the NIH and the DEA to collaborate in developing policies to implement solid scientific investigations that would lead to information assisting physicians in the proper use and prescription of THC in its synthetic or herbal form.”

Diabetes mellitus is a group of autoimmune diseases characterized by defects in insulin secretion resulting in hyperglycemia (an abnormally high concentration of glucose in the blood). There are two primary types of diabetes. Individuals diagnosed with type 1 diabetes (also known as juvenile diabetes) are incapable of producing pancreatic insulin and must rely on insulin medication for survival. Individuals diagnosed with type 2 diabetes (also known as adult onset diabetes) produce inadequate amounts of insulin. Type 2 diabetes is a less serious condition that typically is controlled by diet. Over time, diabetes can lead to blindness, kidney failure, nerve damage, hardening of the arteries and death. The disease is the third leading cause of death in the United States after heart disease and cancer.

Observational trial data published in 2012 in the British Medical Journal previously reported that adults with a history of marijuana use had a lower prevalence of type 2 diabetes and possess a lower risk of contracting the disease than do those with no history of cannabis consumption, even after researchers adjusted for social variables (ethnicity, level of physical activity, etc.) Investigators concluded, “Our analysis of adults aged 20-59 years … showed that participants who used marijuana had a lower prevalence of DM (Diabetes Mellitus) and lower odds of DM relative to non-marijuana users.”

Although subjects who consume marijuana on average have higher average caloric intake levels than non-users, the plant’s use has been associated with lower body-mass index (BMI) and lower rates of obesity.

Abstracts of today’s study, “The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults,” are online here. NORML has additional information and citations regarding cannabis and diabetes in our Library here.

Study: Inhaled Cannabis Reduces Crohn’s Symptoms

May 13th, 2013

Inhaling cannabis reduces symptoms of Crohn’s disease compared to placebo in patients non-responsive to traditional therapies, according to clinical trial data published online ahead of print in the journal Clinical Gastroenterology and Hepatology.

Researchers at the Meir Medical Center, Department of Gastroenterology and Hepatology in Israel assessed the safety and efficacy of inhaled cannabis versus placebo in 21 subjects with Crohn’s disease who were nonresponsive to conventional treatments.

Eleven participants smoked standardized cannabis cigarettes containing 23 percent THC and 0.5 percent CBD (cannabidiol) twice daily over a period of eight weeks. The other ten subjects smoked placebo cigarettes containing no active cannabinoids.

Investigators reported, “Our data show that 8-weeks treatment with THC-rich cannabis, but not placebo, was associated with a significant decrease of 100 points in CDAI (Crohn’s Disease and activity index) scores.” (The CDIA is a research tool used to quantify the symptoms of Crohn’s disease patients.) Five of the eleven patients in the study group also reported achieving disease remission (defined as a reduction in patient CDAI score by more than 150 points).

Researchers also reported that “no significant side effects” were associated with cannabis inhalation. Subjects in the study group reported improvements in appetite and sleep compared to those in the placebo group. Cannabis inhalation was also associated with “significantly less pain” among the participants.

The study is the first placebo-controlled clinical trial to assess the consumption of cannabis for the treatment of Crohn’s.

Israeli researchers had previously published observational trial data reporting that Crohn’s patients require fewer disease-related surgeries following their use of cannabis.

According to survey data published in 2011 in the European Journal of Gastroenterology and Hepatology, some one-half of Crohn’s disease patients acknowledge having used cannabis to mitigate their disease symptoms.

Study: No Association Between The Cumulative Consumption Of Cannabis Smoke And The Risk Of Lung Cancer

May 10th, 2013

In a recent presentation given at the annual meeting of the American Association of Cancer Research, investigators from the university of California, Los Angeles provided the latest data reaffirming that cannabis consumption is not associated with an elevated risk of lung cancer. Below is a summary of the findings from The Oncology Report:

The study included data from six case-control studies conducted from 1999 to 2012 in the United States, Canada, the United Kingdom, and New Zealand, with a subject pool of 2,159 lung cancer cases and 2,985 controls. All of the studies were part of the International Lung Cancer Consortium (ILCCO), an international group of lung cancer researchers with the aim of sharing comparable data from ongoing and recently completed lung cancer studies from different geographical areas and ethnicities.

Dr. Zhang of the University of California, Los Angeles, performed two analyses. One compared all lung cancer cases and all controls, regardless of concurrent or past tobacco use. Then, to reduce confounding by tobacco, she restricted the analysis to those who had never smoked tobacco.

… When compared with cannabis smokers who also used tobacco, habitual pot smokers had no significant increase in cancer risk. In an analysis of marijuana smokers that excluded tobacco smokers, there were no significant differences in any of the comparisons, including habitual vs. nonhabitual use; number of joints smoked per day; duration of up to 20 years or duration of more than 20 years.

The abstract of the presentation, which concludes “Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of lung cancer overall or in never smokers,” is available online here.

Numerous preclinical studies have documented that cannabinoids possess potent anti-cancer properties, including the inhibition of lung cancer cell growth.

Study: Cannabinoid Agonists Mitigate HIV Infection

May 7th, 2013

The administration of synthetic cannabinoid agonists limits HIV infection in macrophages (white blood cells that aid in the body’s immune response), according to preclinical data published in the Journal of Leukocyte Biology. Macrophages are one of the first type of cells infected by the HIV virus when it enters the body.

Investigators at Temple University School of Medicine in Philadelphia assessed the impact of three commercially available synthetic THC agonists on HIV-infected macrophage cells. Following administration, researchers sampled the cells periodically to measure the activity of an enzyme called reverse transcriptase (RT), which is essential for HIV replication. By day 7, investigators reported that the administration of all three compounds was associated with a significant decreased in HIV replication.

Stated a Temple University Health System press release: “The results suggest that selective CB2 (cannabinoid 2 receptor) agonists could potentially be used in tandem with existing antiretroviral drugs, opening the door to the generation of new drug therapies for HIV/AIDS. The data also support the idea that the human immune system could be leveraged to fight HIV infection.”

Patients living with HIV/AIDS frequently report consuming cannabis to counter symptoms of anxiety, appetite loss, chronic pain, and nausea, and one study has reported that patients who use cannabis therapeutically are 3.3 times more likely to adhere to their antiretroviral therapy regimens than non-cannabis users. In preclinical models, the long-term administration of delta-9-THC has recently been associated with decreased mortality and ameliorated disease progression in monkeys. In clinical models, cannabis inhalation is associated with decreased neuropathy and increased levels of appetite hormones in the blood of subjects with HIV infection.

The abstract of the study, “Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists,” appears online here.

Government Accountability Office Says The Drug War Isn’t Working; Did Anybody Think It Was?

April 26th, 2013

The federal government’s anti-drug efforts are inefficient and ineffective, according to a just released report issued by the Congressional watchdog agency, the US Government Accountability Office (GAO).

As if we didn’t know.

The GAO report assessed whether the Obama administration’s anti-drug strategies, as articulated by the White House Office of National Drug Control Policy (the ONDCP aka the Drug Czar’s office) in its 2010 National Drug Control Strategy report, have yet to achieve its stated goals.

The answer? They haven’t.

States the GAO:

“The public health, social, and economic consequences of illicit drug use, coupled with the constrained fiscal environment of recent years, highlight the need to ensure that federal programs efficiently and effectively use their resources to address this problem. ONDCP has developed a 5-year Strategy to reduce illicit drug use and its consequences, but our analysis shows lack of progress toward achieving four of the Strategy’s five goals for which primary data are available.”

In particular, the GAO criticized the administration for failing to adequately address rising levels of youth marijuana consumption. The GAO also rebuffed the ONDCP’s allegation that increased rates adolescent marijuana use are a result of the passage of statewide laws decriminalizing the plant or allowing for its therapeutic use.

“Other factors, including state laws and changing attitudes and social norms regarding drugs, may also affect drug use. We examined studies on three of these other factors, which we refer to as societal factors, which may affect youth marijuana use. … The studies that assessed the effect of medical marijuana laws that met our review criteria found mixed results on effects of the laws on youth marijuana use. … [S]tudies that assessed the effect of marijuana decriminalization that met our review criteria found little to no effect of the laws on youth marijuana use.”

You can read the full GAO report here.

NORML To Provide Educational Content To TheAnswerPage.com

February 22nd, 2013

The National Organization for the Reform of Marijuana Laws is pleased to announce that it is now providing educational content to the editors of The Answer Page, Inc. The Answer Page, Inc. is an online medical educational resource founded in 1998 that provides daily education to healthcare professionals in 120 countries. TheAnswerPage (online at TheAnswerPage.com) uses the Socratic question-and-answer teaching method. The content for the website is primarily written by academic clinicians respected in their fields. All content is peer-reviewed and referenced from current texts and recent literature.

TheAnswerPage now features educational content in the area of medical marijuana. The editorial team of TheAnswerPage states: “Medical marijuana may be controversial, but it is now an important area of study in healthcare. Doctors and healthcare professionals must understand the medical, legal, social and political issues to best respond to their patients’ questions and attend to their needs.”

The medical marijuana ‘lecture series’ begins with an introductory primer to the cannabis plant. The following week focuses on five distinct cannabinoids and their therapeutic potential.

“NORML recognizes that physicians and health care professionals desire balanced information regarding the safety and efficacy of cannabis as a potential therapy,” NORML’s Deputy Director Paul Armentano said. “NORML is pleased to provide its expertise to TheAnswerPage to assist health care professionals better understand and navigate this important public health issue.”

Subscribers to TheAnswerPage receive continuing medical education (CME) credit by reading the content and completing an industry-unique Interactive Crossword Puzzle. The clues are structured to reinforce the educational material, and links are provided to the related content. Subscribers have personal educational accounts that organize their earned CME credit and allow clinicians to download, email or print CME certificates for credentialing and licensing.

TheAnswerPage.com has over 50 interactive crossword puzzles posted, for earning CME credit. New content and crosswords are posted daily.

TheAnswerPage‘s medical cannabis content is available at the ‘syllabus;’ select the pull down menu option: “Medical Marijuana — Medical, Legal, Social, and political Issues.” Free registration to the site is required.